Obiettivo The aim of this project is to perfect a living human skin equivalent using advanced culture procedures and to validate it as reliable predictive in vitro system for human skin pharmaco-toxicology. Human skin was the first organ to be reconstructed in vitro and is likely to provide a predictive system for evaluating drug efficacy and toxicity, avoiding animal experimentation. organogenesis in vitro for pharmacological studies is a very new and promising field of investigation. Culturing cells in close contact with their physiological matrix molecules and with cell types usually adjacent in vivo, cells have been shown to communicate and differentiated in this skin equivalent. These cell-matrix-cell interactions greatly modify the response to pharmaco-toxicological agents, resembling the situation in vivo and demonstrating that some pharmaceutical agents operate on the cell-cell and cell-matrix communication system. To achieve our goal, the collaboration begun during a previous BAP programme will be reinforced in order to study the role of cell-matrix and cell-cell interactions in differentiation processes and in pharmacological responses. The validation of these models with a possible transfer to industry to screen the activity of drugs on a large scale is expected for wound healing promoters, antipsoriatic drugs, pigmentogenic, antineoplastic and anti-ageing substances in the next four years. In addition, this concept of organogenesis in vitro, allowing pharmaco-toxicology at the cellular communication level, will identify pathways that might represent targets for drugs of high socioeconomic value. This first human organ reconstructed in vitro can be considered as a prototype. Most of the technical innovations made with the skin model could be applied to the reconstruction of other organs such as blood vessels, ligaments, endocrine glands, etc. Campo scientifico medical and health sciencesbasic medicinetoxicologymedical and health sciencesbasic medicinepharmacology and pharmacy Programma(i) FP2-BRIDGE - Specific research and technological development programme (EEC) in the field of biotechnology (BRIDGE), 1990-1994 Argomento(i) Data not available Invito a presentare proposte Data not available Meccanismo di finanziamento CSC - Cost-sharing contracts Coordinatore Institut National de la Santé et de la Recherche Médicale Contributo UE Nessun dato Indirizzo Avenue Claude Vellefaux 75475 Paris Francia Mostra sulla mappa Costo totale Nessun dato Partecipanti (4) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto L'Oréal SA Francia Contributo UE Nessun dato Indirizzo 1 rue Eugène Schueller 93600 Aulnay-sous-Bois Mostra sulla mappa Costo totale Nessun dato Stiftung Deutsches Krebsforschungszentrum Germania Contributo UE Nessun dato Indirizzo Im Neuenheimer Feld 280 69120 Heidelberg Mostra sulla mappa Costo totale Nessun dato UNIVERSITAET KOELN Germania Contributo UE Nessun dato Indirizzo Joseph-Stelzmann-Srasse 52 50931 KOELN Mostra sulla mappa Costo totale Nessun dato Université de Liège Belgio Contributo UE Nessun dato Indirizzo 4000 Liège Mostra sulla mappa Costo totale Nessun dato